SCM
MAIA icon

Solas Capital Management’s MAIA Biotechnology MAIA Stock Holding History

Solas Capital Management’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.02M Buy
+4,297,004
New +$7.92M 3.46% 12

Other funds holding MAIA

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Solas Capital Management's MAIA Position: Q1 2026 in Review

Solas Capital Management opened a new position in MAIA Biotechnology (MAIA) in Q1 2026: 4,297,004 shares worth $6.02M. The stake represents 3.46% of the portfolio and ranks #12 among its holdings.

33 funds tracked by Wall St. Rank hold MAIA as of Q1 2026.

  • Solas Capital Management held 4,297,004 shares of MAIA Biotechnology worth $6.02M as of Q1 2026.
  • MAIA Biotechnology was a new Solas Capital Management position in Q1 2026.
  • MAIA Biotechnology made up 3.46% of Solas Capital Management's portfolio in Q1 2026, its #12 holding.
  • 33 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q1 2026.

Based on Solas Capital Management's 13F filing for Q1 2026, filed 15 May 2026.